1 Bortolotti, F. et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 134, 1900-1907, doi:10.1053/j.gastro.2008.02.082 [doi] (2008).
2 European Paediatric Hepatitis, C. V. N. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 41, 45-51, doi:CID35334 [pii] (2005).
3 Jara, P. et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 36, 275-280, doi:CID21154 [pii] (2003).
4 Pokorska-Śpiewak, M. et al. Determinants of liver disease progression in children with chronic hepatitis C virus infection. Pol J Pathol 66, 368-375 (2015).
5 Guido, M. et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? The American Journal of Gastroenterology 98, 660-663, doi:S000292700206015X [pii] (2003).
6 Pokorska-Śpiewak, M. et al. Liver Fibrosis Evaluated With Transient Elastography in 35 Children With Chronic Hepatitis C Virus Infection. Pediatr Infect Dis J 40, 103-108, doi:10.1097/INF.0000000000002913 (2021).
7 Turkova, A. et al. Advanced liver disease in Russian children and adolescents with chronic hepatitis C. J Viral Hepat 26, 881-892, doi:10.1111/jvh.13093 (2019).
8 Modin, L. et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 70, 371-378, doi:10.1016/j.jhep.2018.11.013 (2019).
9 Indolfi, G. et al. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther 52, 1125-1133, doi:10.1111/apt.16037 (2020).
10 Mogahed, E. A. et al. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals. J Pediatr 233, 126-131, doi:10.1016/j.jpeds.2021.02.012 (2021).
11 Indolfi, G. et al. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 66, 505-515, doi:10.1097/MPG.0000000000001872 (2018).
12 Zeng, J. et al. Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years. BMC Pediatr 19, 129, doi:10.1186/s12887-019-1487-6 (2019).
13 Castera, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343-350, doi:S0016508504020293 [pii] (2005).
14 Sasso, M., Miette, V., Sandrin, L. & Beaugrand, M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 36, 13-20, doi:10.1016/j.clinre.2011.08.001 (2012).
15 Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md.) 43, 1317-1325, doi:10.1002/hep.21178 (2006).
16 Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518-526, doi:10.1053/jhep.2003.50346 (2003).
17 Lin, Z. H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology (Baltimore, Md.) 53, 726-736, doi:10.1002/hep.24105 [doi] (2011).
18 Balistreri, W. F. et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 66, 371-378, doi:10.1002/hep.28995 (2017).
19 Schwarz, K. B. et al. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology 71, 422-430, doi:10.1002/hep.30830 (2020).
20 Murray, K. F. et al. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology 68, 2158-2166, doi:10.1002/hep.30123 (2018).
21 Rogers, M. E. & Balistreri, W. F. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 27, 1117-1131, doi:10.3748/wjg.v27.i12.1117 (2021).
22 Chen, S. H. et al. Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C. PLoS One 13, e0190455, doi:10.1371/journal.pone.0190455 (2018).
23 Rockey, D. C. Fibrosis reversal after hepatitis C virus elimination. Curr Opin Gastroenterol 35, 137-144, doi:10.1097/MOG.0000000000000524 (2019).
24 Knop, V. et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 23, 994-1002, doi:10.1111/jvh.12578 (2016).
25 Bachofner, J. A. et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 37, 369-376, doi:10.1111/liv.13256 (2017).
26 Chan, P. P. Y., Levy, M. T., Shackel, N., Davison, S. A. & Prakoso, E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int 19, 541-546, doi:10.1016/j.hbpd.2020.06.013 (2020).
27 Makhlouf, N. A. et al. Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness. J Pediatric Infect Dis Soc 10, 7-13, doi:10.1093/jpids/piaa006 (2021).
28 Pokorska-Śpiewak, M. & Śpiewak, M. Management of hepatitis C in children and adolescents during COVID-19 pandemic. World J Hepatol 12, 485-492, doi:10.4254/wjh.v12.i8.485 (2020).